The deadline of follow‐up was December 2021, and the median follow‐up time was 22.89.Patient's condition progressed, we followed up with the patients on their subsequent treatment. Some patients underwent optimal supportive care, some received immune therapy combined with chemotherapy, while others underwent simple chemotherapy or immune therapy. There was no statistically significant difference in the subsequent treatment plans between the experimental group and the control group (Table Posttreatment in two groups.In the control group, the PFS and OS median of patients were 3.37 (95% CI: 3.00–3.90) months and 5.3 (95% CI: 4.43–6.88) months, respectively. In the experiment group, the PFS and OS median of patients were 3.91 (95% CI: 3.55–4.50) months and 7.0 (95% CI: 5.85–8.15) months, respectively. There was statistical significance of PFS and OS between two groups (PFS OS and PFS curves were estimated by the Kaplan–Meier method. (A) PFS of two groups. (B) OS of two groups. (C) PFS subgroup analysis for two groups. (D) OS subgroup analysis for two groups. C‐S‐L: control second line. E‐S‐L: experiment second line.In subgroup analysis in the second‐line treatment, the PFS median of control and experiment group were 3.90 (95% CI: 3.80–4.20) and 4.60 (95% CI: 4.50–4.75) months, respectively OS median were 6.95 (95% CI: 6.39–7.50) and 8.5 (95% CI: 7.24–9.76) months, respectively, which had statistically significant differences of PFS or OS between the two groups. (PFS 